AGEN—+17%/AH—on FDA approval of GSK’s Shingrix shingles vaccine, which incorporates AGEN’s QS-21 adjuvant: https://finance.yahoo.com/news/shingrix-approved-us-prevention-shingles-231600127.html https://finance.yahoo.com/news/fda-approves-gsks-shingles-vaccine-230000187.html Because of QS-21, AGEN will earn a small royalty from GSK on sales of Shingrix. AGEN obtained QS-21 way back in 2000 via the acquisition of the failed biotech, Aquila Pharmaceuticals (http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=26759 ). QS-21 is also a component of AGEN's neoantigen-cancer-vaccine program (such as it is).